Intellectual Property

Our Leading IP Position

Expanding our intellectual property portfolio is essential in order to successfully implement our strategy and reach our ambition to become a leading biotech in the microbiome industry.

By filing our own IP in the US and Europe, and by licensing in available patents from world class academic, we are building a leadership IP position in the Christensenella space.

YSOPIA Bioscience filed proprietary patent families protecting christensenella modulation for therapeutic use.

In September 2018, we acquired an exclusive licence for the Christensenella patents from Cornell University (Ithaca, NY, USA) covering the applications of Christensenella as a treatment for obesity and metabolic diseases. We’ve also had a number of patents granted by the USPTO.

In April 2020, YSOPIA Bioscience entered into an exclusive license agreement with Spanish National Research Council (CSIC), for its patent application dedicated to the therapeutic use of Christensenella gut bacteria in mood disorders
Read our press release

 

We are actively scouting at the international level for patent licensing opportunities in order to continue expanding our intellectual property portfolio.

> Discover our pipeline

Microbiome & us
News
Jul 6, 2021
YSOPIA Successfully Completes Phase 1 Clinical Study of Xla1 Biotherapy for the Treatment of Obesity and Metabolic...
> more
Jun 1, 2021
90 seconds to learn more about YSOPIA Bioscience | [video width="1080" height="1080"...
> more
Press / Media
Sep 13, 2021
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) apply an aligned and complimentary...
> more
Jun 16, 2021
Forte de la découverte de Christensenella, une bactérie naturellement présente dans les microbiotes sains, la...
> more
Publications
Sep 1, 2021
Héloïse Tudela, Sandrine P. Claus and Maya Saleh Access the full paper The community of the diverse microorganisms...
> more
Aug 11, 2021
Jeanne-Céleste Paquet, Sandrine P. Claus, Magali Cordaillat-Simmons, Wilfrid Mazier, Georges Rawadi, Laure Rinaldi,...
> more
now on twitter
YSOPIA Bioscience

YSOPIA Bioscience will be presenting a poster highlighting safety and first efficacity results of its Xla1 biothera… t.co/8rMu707lq5

YSOPIA Bioscience © 2021 - all rights reserved terms and conditions